慢性腎臓病（ＣＫＤ）における腎性貧血管理の現況

DOI Web Site 被引用文献2件 参考文献12件

書誌事項

タイトル別名
  • Current management of renal anemia in patients with chronic kidney disease at the predialysis stage
  • マンセイ ジンゾウビョウ CKD ニ オケル ジンセイ ヒンケツ カンリ ノ ゲンキョウ

この論文をさがす

抄録

Objective: Patients with chronic kidney disease (CKD) are frequently complicated by renal anemia as renal function declines. However, clinical guidelines on erythrocyte stimulating agents (erythropoietin: EPO) for such patients have not been established. Current clinical practice for EPO administration is based on the recommendations of the Japanese health insurance regulations, which have not always been supported by clinical evidence.<br>Materials & Methods: The study subjects were 49 patients with CKD staged above 3 who had developed renal anemia requiring EPO. These patients were treated with EPO S. C. at the dose of 6, 000IU/week together with iron supplementation as deemed necessary for more than 24 weeks.<br>Results: The hemoglobin (Hb) value was 9.2±1.0g/dL at the start, 10.9±1.6g/dL at the peak (n=49, p<0.001 the start vs. the peak), and 9.0±1.6g/dL at the commencement of dialysis (n=49, p<0.001 the peak vs. the commencement of dialysis). Seventy-one percent (35/49) of the patients achieved Hb levels over 10g/dL, and 51% (25/49) achieved Hb levels over 11g/dL. Conversely, 28% (14/49) of the patients failed to reach an Hb level over 10g/dL. Factors explaining the good response to EPO (good responders were defined as those achieving Hb levels over 11g/dL) had shown high Hb levels at the start (Logistic multiple regression analysis, p=0.03) along with low creatinine concentration at the start (Cox's proportional hazard models, p=0.015). Transferrin saturation (TSAT) at the start was 33.6±13.6%, 34.0±19.9% at the peak, and 24.7±11.6% at the commencement of dialysis, showing a significant reduction in TSAT at the commencement of dialysis compared to that at the start (n=49, p=0.0383, the start vs. the commencement of dialysis). Serum ferritin concentration was 140.7±139.5pg/mL at the start, 107.9±110.8pg/mL at the peak, and 131.9±112.4pg/mL at the commencement of dialysis, indicating an absence of significant differences among the three time points.<br>Conclusion: The current health insurance regulations in Japan seem to be inappropriate in that the permitted EPO dosage of 6, 000IU/week might not be sufficient to achieve the target Hb level of more than 11g/dL in most patients with CKD. To more efficiently achieve renoprotection, both early and timely initiation of EPO and reconsideration of the recommended EPO dosage appear to be warranted.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (12)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ